Binimetinib

Small molecule

Also known as MEK162

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, Melanoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (3)
CA
  • MEKTOVI (binimetinib) is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test. Clinical data supporting the use of MEKTOVI in the treatment of patients with BRAF V600 mutations are limited to patients with V600E or V600K mutations.
Product first approved 2021Health Canada
JP
  • Unresectable melanoma with a BRAF mutation, in combination with encorafenib (MEKTOVI tablets)
Product first approved 2019ono-pharma.com
EU
  • MelanomaBinimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.Non-small cell lung cancer (NSCLC)Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.
Product first approved 2018EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (8)
Melanoma
NCT05270044 · Pierre Fabre Medicament
2022-05-02 – 2035-05-02 · Melanoma
What this study did
NCT04657991 · Pfizer
2021-01-15 – 2026-10-30 · Melanoma
What this study did
Other / comorbidity
NCT05615818 · UNICANCER
2024-07-18 – 2028-06 · Biliary Tract Neoplasms
What this study did
NCT03803553 · Massachusetts General Hospital
2020-04-16 – 2027-12 · Metastatic Colon Cancer, Stage III Colon Cancer
What this study did
NCT01849874 · Pfizer
2013-06-27 – 2022-08-23 · Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal Cancer
What this study did
Phase 2 (54)
Melanoma
NCT03563729 · Inge Marie Svane
2018-06-06 – 2028-06-06 · Malignant Melanoma
What this study did
NCT04598009 · University of California, San Francisco
2021-03-03 – 2028-05-31 · Melanoma Stage III, Melanoma Stage IV
What this study did
NCT05097378 · CCTU- Cancer Theme
2023-02-27 – 2028-05-31 · Melanoma, Cancer
What this study did
NCT06887088 · Grupo Español Multidisciplinar de Melanoma
2025-05-29 – 2028-01 · Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases
What this study did
NCT05170334 · H. Lee Moffitt Cancer Center and Research Institute
2021-12-15 – 2028-01 · Metastatic Uveal Melanoma
What this study did
NCT02465060 · National Cancer Institute (NCI)
2015-08-17 – 2027-12-31 · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
What this study did
NCT02910700 · M.D. Anderson Cancer Center
2016-12-09 – 2027-12-08 · Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
What this study did
NCT04511013 · SWOG Cancer Research Network
2021-01-06 – 2027-06-30 · Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
What this study did
NCT04074096 · UNICANCER
2022-09-05 – 2027-03-27 · Malignant Melanoma, BRAF V600 Mutation, Brain Metastases
What this study did
NCT05026983 · M.D. Anderson Cancer Center
2021-12-27 – 2027-02-02 · Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
What this study did
NCT03235245 · European Organisation for Research and Treatment of Cancer - EORTC
2018-10-30 – 2027-01 · Unresectable Stage III Melanoma, Stage IV Melanoma
What this study did
NCT05767879 · Leiden University Medical Center
2022-01-01 – 2026-01-01 · Melanoma Stage III, In-Transit Metastasis of Cutaneous Melanoma
What this study did
NCT05304546 · Dr. Ronnie Shapira
2023-09-05 – 2025-07-17 · Malignant Melanoma, Metastatic Melanoma, Immunotherapy, BRAF V600E, Malignant Melanoma Stage IV
What this study did
NCT04221438 · ECOG-ACRIN Cancer Research Group
2021-09-22 – 2025-01-31 · Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma
What this study did
NCT04375527 · Jonsson Comprehensive Cancer Center
2020-12-03 – 2024-11-22 · Clinical Stage III Cutaneous Melanoma AJCC V8, Clinical Stage IV Cutaneous Melanoma AJCC V8, Locally Advanced Cutaneous Melanoma, Metastatic Cutaneous Melanoma, Pathologic Stage III Cutaneous Melanoma AJCC V8, Pathologic Stage IIIA Cutaneous Melanoma AJCC V8, Pathologic Stage IIIB Cutaneous Melanoma AJCC V8, Pathologic Stage IIIC Cutaneous Melanoma AJCC V8, Pathologic Stage IIID Cutaneous Melanoma AJCC V8, Pathologic Stage IV Cutaneous Melanoma AJCC V8, Unresectable Cutaneous Melanoma
What this study did
NCT02631447 · Fondazione Melanoma Onlus
2016-11-14 – 2024-05-31 · Metastatic Melanoma
What this study did
NCT03898908 · Grupo Español Multidisciplinar de Melanoma
2019-07-18 – 2023-07-31 · Metastatic Melanoma, Brain Metastases
What this study did
NCT01320085 · Pfizer
2011-03-24 – 2023-02-06 · BRAF or NRAS Mutant Metastatic Melanoma
What this study did
NCT02159066 · Pfizer
2014-07-23 – 2023-01-10 · Melanoma
What this study did
NCT02263898 · Jonsson Comprehensive Cancer Center
2015-01 – 2020-12 · Recurrent Melanoma, Stage IV Melanoma
What this study did
NCT02094872 · Yale University
2014-05 – 2018-12 · Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT04526782 · Intergroupe Francophone de Cancerologie Thoracique
2021-01-19 – 2027-03 · Non Small Cell Lung Cancer, BRAF V600E
What this study did
NCT05195632 · Pierre Fabre Medicament
2022-06-02 – 2026-12-14 · Non-Small Cell Lung Cancer
What this study did
NCT04735068 · Abramson Cancer Center at Penn Medicine
2021-04-09 – 2023-12-31 · Non-Small Cell Lung Cancer, KRAS Mutation-Related Tumors
What this study did
NCT02276027 · Novartis Pharmaceuticals
2015-01-20 – 2019-10-15 · Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma
What this study did
Other / comorbidity
NCT05564377 · National Cancer Institute (NCI)
2023-04-07 – 2030-07-01 · Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
What this study did
NCT04324112 · National Cancer Institute (NCI)
2020-10-28 – 2029-06-30 · Hairy Cell Leukemia
What this study did
NCT06207656 · Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
2024-04-16 – 2029-04-01 · Colorectal Cancer
What this study did
NCT04061980 · Providence Health & Services
2020-10-30 – 2028-12-30 · BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8
What this study did
NCT06159478 · National Cancer Center, Japan
2023-06-30 – 2028-09-30 · Low-grade Glioma, Pancreatic Cancer
What this study did
NCT05554367 · National Cancer Institute (NCI)
2023-12-13 – 2028-08-26 · Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT04322383 · National Cancer Institute (NCI)
2021-01-07 – 2028-07-31 · Hairy Cell Leukemia
What this study did
NCT05564403 · National Cancer Institute (NCI)
2024-02-09 – 2027-10-15 · Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma, Recurrent Biliary Tract Carcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Biliary Tract Carcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
What this study did
NCT05286788 · Nationwide Children's Hospital
2023-04-10 – 2027-04-10 · Adamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
What this study did
NCT04439344 · National Cancer Institute (NCI)
2016-05-31 – 2027-03-31 · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
What this study did
NCT03971409 · Laura Huppert, MD, BA
2019-07-08 – 2027-01-31 · Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
What this study did
NCT03839342 · University Health Network, Toronto
2019-06-07 – 2026-12 · Solid Tumor
What this study did
NCT05554354 · National Cancer Institute (NCI)
2024-09-13 – 2025-04-04 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
What this study did
NCT05510895 · AIO-Studien-gGmbH
2022-09-01 – 2025-01-31 · Colorectal Cancer, Colon Cancer, BRAF V600E, BRAF V600 Mutation, Localized Cancer
What this study did
NCT03981614 · Academic and Community Cancer Research United
2019-10-29 – 2024-07-02 · Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Carcinoma
What this study did
NCT05097599 · Strata Oncology
2022-04-29 – 2024-06-12 · Cancer, Advanced Solid Tumor
What this study did
NCT03231306 · University of Alabama at Birmingham
2017-11-28 – 2024-04-17 · Neurofibromatosis Type 1, Plexiform Neurofibroma
What this study did
NCT03475004 · University of Colorado, Denver
2018-09-17 – 2024-02-12 · Colorectal Cancer, Metastatic Cancer
What this study did
NCT04390243 · Academic and Community Cancer Research United
2020-11-16 – 2023-11-01 · Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT03973918 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2019-07-29 – 2023-10-01 · High Grade Glioma, BRAF V600E, BRAF V600K, Anaplastic Astrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Gliosarcoma, Glioblastoma
What this study did
NCT03693170 · Pierre Fabre Medicament
2019-01-17 – 2023-04-27 · BRAF V600E-mutant Metastatic Colorectal Cancer
What this study did
NCT02834364 · University of Heidelberg Medical Center
2016-06 – 2023-03-29 · Relapsed or Refractory Multiple Myeloma, Patients With BRAFV600 E or BRAFV600K Mutation
What this study did
Phase 1/2 (23)
Melanoma
NCT03947385 · IDEAYA Biosciences
2019-06-28 – 2027-06-15 · Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
What this study did
NCT05340621 · OnKure, Inc.
2022-05-11 – 2025-01-29 · RAS Mutation, NRAS Gene Mutation, Melanoma
What this study did
NCT04720768 · Peter MacCallum Cancer Centre, Australia
2020-06-04 – 2024-12-04 · Melanoma, Metastasis
What this study did
NCT02902042 · Prof. Dr. med. Dirk Schadendorf
2018-04-24 – 2020-11-30 · Malignant Melanoma
What this study did
NCT01781572 · Pfizer
2013-06 – 2018-02-20 · Locally Advanced or Metastatic NRAS Mutant Melanoma
What this study did
NCT01801358 · Array Biopharma, now a wholly owned subsidiary of Pfizer
2013-08 – 2015-05 · Uveal Melanoma
What this study did
NCT01562899 · Pfizer
2012-08-27 – 2015-04-01 · Metastatic Pancreatic Adenocarcinoma, BRAF Mutated Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT04585815 · Pfizer
2020-11-10 – 2024-10-29 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT04720976 · Allist Pharmaceuticals, Inc.
2021-03-23 – 2023-12-19 · Solid Tumor, NSCLC
What this study did
NCT04292119 · Massachusetts General Hospital
2020-05-01 – 2023-03-01 · Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation, ROS1 Rearrangement, Relapsed Cancer, MET Amplification, Resistant Cancer, NSCLC
What this study did
Other / comorbidity
NCT05080621 · Deciphera Pharmaceuticals, LLC
2021-11 – 2027-05 · Gastrointestinal Stromal Tumors
What this study did
NCT01991379 · Memorial Sloan Kettering Cancer Center
2013-11 – 2026-11 · Gastrointestinal Stromal Tumor (GIST)
What this study did
NCT02285439 · Children's Hospital Los Angeles
2016-05-04 – 2025-08-01 · Low-Grade Gliomas, Malignant Neoplasms, Brain, Soft Tissue Neoplasms
What this study did
NCT04494958 · Fundacion Oncosur
2020-11-18 – 2023-12-14 · Triple Negative Breast Cancer
What this study did
NCT03843775 · Memorial Sloan Kettering Cancer Center
2019-02-14 – 2023-09-02 · Advanced BRAF Mutant Cancers
What this study did
NCT01543698 · Pfizer
2012-05-28 – 2023-03-09 · Solid Tumors Harboring a BRAF V600 Mutation
What this study did
NCT03106415 · Mayo Clinic
2017-09-27 – 2022-05-19 · Breast Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
What this study did
NCT03637491 · Pfizer
2018-08-15 – 2021-02-02 · Pancreatic Cancer
What this study did
NCT02089230 · M.D. Anderson Cancer Center
2014-08-27 – 2019-06-05 · Leukemia
What this study did
NCT01828034 · Memorial Sloan Kettering Cancer Center
2013-04 – 2019-05-30 · Advanced Biliary Tract Carcinoma
What this study did
NCT02773459 · Seoul National University Hospital
2016-04 – 2019-01-07 · Biliary Tract Cancer
What this study did
NCT01927341 · Pfizer
2013-11-19 – 2016-01-25 · Metastatic Colorectal Cancer
What this study did
Phase 1 (41)
Melanoma
NCT04903119 · Rina Plattner
2022-06-01 – 2030-06-01 · Metastatic Melanoma, BRAF Gene Mutation
What this study did
NCT04741997 · H. Lee Moffitt Cancer Center and Research Institute
2021-05-24 – 2027-04 · Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
What this study did
NCT03543969 · H. Lee Moffitt Cancer Center and Research Institute
2018-06-14 – 2026-12 · Melanoma (Skin), Skin Cancer, Skin Melanoma, Skin Carcinoma
What this study did
NCT03864042 · Pfizer
2018-01-02 – 2023-05-29 · Advanced Solid Tumors, Metastatic Melanoma
What this study did
NCT04759846 · Pierre Fabre Medicament
2021-01-21 – 2023-05 · BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma, Hepatic Impairment
What this study did
NCT05810740 · Pierre Fabre Medicament
2022-08-31 – 2023-01-18 · Melanoma, BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma
What this study did
NCT05103891 · Pierre Fabre Medicament
2021-09-03 – 2021-11-29 · Melanoma, BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT04913285 · Pierre Fabre Medicament
2021-08-04 – 2029-03-30 · Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
What this study did
NCT05355701 · Pfizer
2022-07-05 – 2027-08-31 · Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma, Advanced Colorectal Cancer (Part 1)
What this study did
NCT03991819 · University Health Network, Toronto
2019-09-20 – 2026-12 · Non-small Cell Carcinoma
What this study did
NCT04870034 · Roswell Park Cancer Institute
2024-01-15 – 2026-09-30 · Colorectal Carcinoma, Lung Adenocarcinoma, Malignant Solid Neoplasm, Pancreatic Carcinoma
What this study did
NCT04892017 · Deciphera Pharmaceuticals, LLC
2021-06-15 – 2026-03-30 · Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
What this study did
NCT03170206 · Dana-Farber Cancer Institute
2017-05-31 – 2025-12-31 · Lung Cancer
What this study did
NCT04543188 · Pfizer
2021-01-08 – 2024-03-20 · Malignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary, Brain Neoplasms, Malignant Neoplasms
What this study did
NCT04965818 · Taiho Oncology, Inc.
2021-09-20 – 2023-09-21 · Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer, KRAS Gene Mutation
What this study did
NCT04005144 · University of California, San Francisco
2020-02-25 – 2022-10-01 · ALK Gene Rearrangement, Lung Non-Small Cell Carcinoma, Progressive Disease, ROS1 Gene Rearrangement, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer
What this study did
NCT02964689 · Swiss Cancer Institute
2017-04-12 – 2021-07-02 · Advanced Non-small Cell Lung Cancer, KRAS Gene Mutation, Lung Cancer
What this study did
NCT01859026 · H. Lee Moffitt Cancer Center and Research Institute
2013-12-30 – 2019-08-22 · Lung Cancer, Non-Small Cell Lung Cancer
What this study did
NCT02451865 · Jonsson Comprehensive Cancer Center
2016-06 – 2019-06 · Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT05111561 · National Cancer Institute (NCI)
2022-08-02 – 2027-03-14 · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
What this study did
NCT04132505 · M.D. Anderson Cancer Center
2019-10-22 – 2026-03-24 · Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT04800822 · Pfizer
2021-03-17 – 2024-06-19 · Solid Tumor
What this study did
NCT02613650 · University of Utah
2016-08-19 – 2022-12-21 · Advanced KRAS Positive Metastatic Colorectal Cancer
What this study did
NCT04044430 · University of California, San Francisco
2020-08-31 – 2022-07-31 · Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer, Stage III Colorectal Cancer, Stage III Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Colorectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Colorectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Colorectal Cancer, Stage IIIC Rectal Cancer, Stage IV Colon Cancer, Stage IV Colorectal Cancer, Stage IV Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Colorectal Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Colorectal Cancer, Stage IVB Rectal Cancer, Stage IVC Colon Cancer, Stage IVC Colorectal Cancer, Stage IVC Rectal Cancer
What this study did
NCT03158103 · Memorial Sloan Kettering Cancer Center
2017-04-15 – 2021-04-28 · Gastrointestinal Stromal Tumor (GIST)
What this study did
NCT02185690 · University Health Network, Toronto
2017-03-07 – 2019-07-04 · Lungcancer
What this study did
NCT02510001 · University of Oxford
2014-11 – 2018-12-03 · Solid Tumor, Colorectal Cancer
What this study did
NCT01469130 · Array Biopharma, now a wholly owned subsidiary of Pfizer
2011-11 – 2018-02-01 · Advanced Solid Tumor
What this study did
NCT02041481 · City of Hope Medical Center
2014-07-16 – 2018-01-19 · Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
What this study did
NCT01363232 · Array Biopharma, now a wholly owned subsidiary of Pfizer
2011-08 – 2017-12-18 · Advanced Solid Tumors, Selected Solid Tumors
What this study did
NCT02049801 · Bruno C. Medeiros
2014-12 – 2017-11-01 · Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
What this study did
NCT01449058 · Array BioPharma
2012-03 – 2017-08-15 · Advanced and Selected Solid Tumors, AML, High Risk and Very High Risk MDS
What this study did
NCT02050815 · Array Biopharma, now a wholly owned subsidiary of Pfizer
2014-03 – 2016-08-26 · Hepatic Impairment
What this study did
NCT01649336 · Array Biopharma, now a wholly owned subsidiary of Pfizer
2012-07 – 2016-03 · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
What this study did
NCT02105350 · University Health Network, Toronto
2015-06 – 2015-06 · Biliary Tract Carcinoma, Gallbladder Carcinoma
What this study did
NCT01352273 · Array Biopharma, now a wholly owned subsidiary of Pfizer
2011-06 – 2013-09 · Advanced Solid Tumors
What this study did
NCT01337765 · Pfizer
2011-07-08 – 2013-03-22 · Unspecified Adult Solid Tumor, Protocol Specific, Solid Tumor
What this study did
NCT00959127 · Array Biopharma, now a wholly owned subsidiary of Pfizer
2009-08 – 2013-01 · Advanced Solid Tumors, Advanced or Metastatic Biliary Cancer, Metastatic Colorectal Cancer
What this study did
Phase 4 (2)
Melanoma
Other / comorbidity
Early phase / not applicable (1)
Other / comorbidity
NCT04801966 · Peter MacCallum Cancer Centre, Australia
2021-09-23 – 2022-12-30 · Cancer
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Melanoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Binimetinib: this drugApprovedSmall moleculeMEK1/2Partial signal
NCT01763164: Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (From the date of randomization to the date of the first documented PD or death, whichever occurred first (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)): Binimetinib (MEK162) 2.83 Months (95% CI 2.76 to 3.55) | Dacarbazine 1.51 Months (95% CI 1.48 to 1.71)
Aldesleukin (Proleukin)ApprovedRecombinant Cytokine (il-2)Interleukin-2 receptor (IL-2R)not yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
CobimetinibApprovedSmall moleculeMEK1/2Reliable signalNo reviewed efficacy summary in this indication
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Reliable signal
NCT01597908: Overall Survival (OS) (From the date of randomization until date of death due to any cause (up to approximately 6 years)): Dabrafenib Plus Trametinib 26 Months (95% CI 22.1 to 33.8) | Vemurafenib 17.8 Months (95% CI 15.6 to 20.7)
NCT01584648: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)): Dabrafenib + Trametinib 10.2 Months (95% CI 8.1 to 12.8) | Dabrafenib + Placebo 8.8 Months (95% CI 5.9 to 9.3)
EncorafenibApprovedSmall moleculeBRAF V600EPartial signalNo reviewed efficacy summary in this indication
Interferon Alfa-2b (Intron A)ApprovedBiologic (subtype unspecified)Type I interferon receptorPartial signal
NCT01359956: Overall survival, interferon alfa-2b added vs not added to dacarbazine-based chemotherapy (2x2 factorial): HR 0.92 (95% CI 0.70 to 1.20), p=0.68 (Daponte et al., J Transl Med 2013). missed
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT00094653: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone (From randomization until the end of the study, which was defined as the time at which 481 deaths were observed (264 weeks)): Ipilimumab Plus gp100 9.95 months (95% CI 8.48 to 11.5) | gp100 6.44 months (95% CI 5.49 to 8.71)
Lifileucel (Amtagvi)ApprovedCell therapyTumor-infiltrating lymphocytes (polyclonal tumor antigens)not yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02388906: Recurrence-free Survival (RFS) (up to 36 months): Nivolumab 3 mg/kg 52.37 Months | Ipilimumab 10 mg/kg 24.08 Months (95% CI 16.56 to 35.09)
NCT01721746: CheckMate 037 coprimaries: objective response rate 31.7% (95% CI 23.5 to 40.8) in the first 120 nivolumab patients vs 10.6% (3.5 to 23.1) with investigator-choice chemotherapy at the interim analysis, reported without a between-group p-value; overall survival median 16 vs 14 months (HR 0.95, 95.54% CI 0.73 to 1.24), no difference (Weber, Lancet Oncol 2015; Larkin, JCO 2018). missed
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
RelatlimabApprovedMonoclonal antibodyLAG-3Reliable signal
NCT03470922: Progression Free Survival (PFS) (From randomization to date of first documented tumor progression or death (up to approximately 33 months)): Arm A: Relatlimab + Nivolumab 10.12 Months (95% CI 6.37 to 15.74) | Arm B: Nivolumab 4.63 Months (95% CI 3.38 to 5.62)
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
TrametinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
VemurafenibApprovedSmall moleculeBRAF (V600 mutant)Partial signalNo reviewed efficacy summary in this indication
Vusolimogene Oderparepvec (Tudriqev)ApprovedOncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
CemiplimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
FianlimabPhase 3Monoclonal antibodyLAG-3not yet gradedNo reviewed efficacy summary in this indication
Intismeran AutogenePhase 3VaccinePatient-specific tumor neoantigens (personalized, up to 34 per patient)not yet gradedNo reviewed efficacy summary in this indication
Tebentafusp-Tebn (KIMMTRAK)Phase 3Protein / enzyme therapeuticgp100-HLA-A*02:01 x CD3Partial signalNo reviewed efficacy summary in this indication
LNS8801Phase 2/3Small moleculeGPER (G protein-coupled estrogen receptor)not yet gradedNo reviewed efficacy summary in this indication
ResiquimodPhase 2/3Small moleculeToll-like receptor 7 and 8 (TLR7/8)not yet gradedNo reviewed efficacy summary in this indication
HS-IT101Phase 2Cell therapyAutologous tumor neoantigens (polyclonal, patient-specific)not yet gradedNo reviewed efficacy summary in this indication
VSV-IFNβ-NISPhase 2Oncolytic virusOncolytic VSV expressing interferon-beta and NISnot yet gradedNo reviewed efficacy summary in this indication
EvalstotugPhase 1/2Biologic (subtype unspecified)CTLA-4not yet gradedNo reviewed efficacy summary in this indication
OBX-115Phase 1/2Cell therapyIL-15 receptor signalingnot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
NaporafenibDiscontinuedSmall moleculePan-RAFnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(26 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Binimetinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
November 2026 (1)
Phase 1/2Gastrointestinal Stromal Tumor (GIST)Active not recruiting
Est. primary completion 2026-11 · NCT01991379 · CT.gov ↗
What to watch
December 2026 (2)
Phase 2Solid TumorActive not recruiting
Est. primary completion 2026-12 · NCT03839342 · CT.gov ↗
What to watch
Phase 3Metastatic Colon Cancer, Stage III Colon CancerActive not recruiting
Est. primary completion 2026-12 · NCT03803553 · CT.gov ↗
What to watch
2027 (14)
January 2027 (2)
Phase 1/2MelanomaRecruiting
Est. primary completion 2027-01-29 · NCT03947385 · CT.gov ↗
What to watch
Phase 2Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer …Active not recruiting
Est. primary completion 2027-01-31 · NCT03971409 · CT.gov ↗
What to watch
February 2027 (1)
Phase 2MelanomaRecruiting
Est. primary completion 2027-02-02 · NCT05026983 · CT.gov ↗
What to watch
March 2027 (2)
Phase 1Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm …Recruiting
Est. primary completion 2027-03-14 · NCT05111561 · CT.gov ↗
What to watch
Phase 3MelanomaActive not recruiting
Est. primary completion 2027-03-31 · NCT05270044 · CT.gov ↗
What to watch
April 2027 (2)
Phase 1MelanomaRecruiting
Est. primary completion 2027-04 · NCT04741997 · CT.gov ↗
What to watch
Phase 2Adamantinous Craniopharyngioma, Recurrent Adamantinomatous CraniopharyngiomaRecruiting
Est. primary completion 2027-04-10 · NCT05286788 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2MelanomaRecruiting
Est. primary completion 2027-05-31 · NCT04598009 · CT.gov ↗
What to watch
June 2027 (2)
Phase 3Biliary Tract NeoplasmsRecruiting
Est. primary completion 2027-06 · NCT05615818 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2027-06-30 · NCT04511013 · CT.gov ↗
What to watch
August 2027 (1)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-08-31 · NCT05355701 · CT.gov ↗
What to watch
December 2027 (3)
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-12-08 · NCT02910700 · CT.gov ↗
What to watch
Phase 2BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma …Active not recruiting
Est. primary completion 2027-12-30 · NCT04061980 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-12-31 · NCT02465060 · CT.gov ↗
What to watch
2028 (6)
January 2028 (1)
Phase 2MelanomaRecruiting
Est. primary completion 2028-01 · NCT06887088 · CT.gov ↗
What to watch
February 2028 (1)
Phase 2Low-grade Glioma, Pancreatic CancerRecruiting
Est. primary completion 2028-02-28 · NCT06159478 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Hairy Cell LeukemiaRecruiting
Est. primary completion 2028-04-30 · NCT04322383 · CT.gov ↗
What to watch
July 2028 (1)
Phase 1MelanomaRecruiting
Est. primary completion 2028-07-01 · NCT04903119 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Stage IV Ovarian Cancer AJCC v8 …Active not recruiting
Est. primary completion 2028-08-26 · NCT05554367 · CT.gov ↗
What to watch
November 2028 (1)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-11-30 · NCT04913285 · CT.gov ↗
What to watch
2029 (2)
April 2029 (1)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2029-04-01 · NCT06207656 · CT.gov ↗
What to watch
July 2029 (1)
Phase 4Solid TumorsRecruiting
Est. primary completion 2029-07-31 · NCT05203172 · CT.gov ↗
What to watch
2030 (1)
July 2030 (1)
Phase 2Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 …Recruiting
Est. primary completion 2030-07-01 · NCT05564377 · CT.gov ↗
What to watch

See the full readout calendar ↗